Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Alexander MuikElena GarraldaIsil AltintasFriederike GiesekeRavit GevaEytan Ben-AmiCorinne Maurice-DrorEmiliano CalvoPatricia M LoRussoGuzman AlonsoMaria E Rodriguez-RuizKristina B SchoedelJordan M BlumBianca SängerTheodora W SalcedoSaskia M BurmEliana StanganelloDennis VerzijlFulvia VascottoAngelica SetteJuliane QuinkhardtTheo S PlantingaAras TokerEdward N van den BrinkMark FereshtehMustafa DikenDavid SatijnSebastian KreiterEsther C W BreijGaurav BajajEleni LagkadinouKate SasserÖzlem TüreciUlf ForssmannTahamtan AhmadiUğur ŞahinMaria Jure-KunkelIgnacio Melero BermejoPublished in: Cancer discovery (2022)
DuoBody-PD-L1×4-1BB (GEN1046) is a first-in-class bispecific immunotherapy with a manageable safety profile and encouraging preclinical and early clinical activity. With its ability to confer clinical benefit in tumors typically less sensitive to CPIs, GEN1046 may fill a clinical gap in CPI-relapsed or refractory disease or as a combination therapy with CPIs. See related commentary by Li et al., p. 1184. This article is highlighted in the In This Issue feature, p. 1171.